Journal of Blood Disorders & Transfusion

Strengthening Transfusion Safety through Comprehensive Hemovigilance Surveillance Systems

Orm Steien^* Department of Hematology and Transfusion Medicine, Northern Fjord University, Tromsø, Norway
^*Correspondence: Orm Steien, Department of Hematology and Transfusion Medicine, Northern Fjord University, Tromsø, Norway, Email:

Received: 27-Feb-2026, Manuscript No. JBDT-26-31748; Editor assigned: 02-Mar-2026, Pre QC No. JBDT-26-31748 (PQ); Reviewed: 16-Mar-2026, QC No. JBDT-26-31748; Revised: 23-Mar-2026, Manuscript No. JBDT-26-31748; Published: 30-Mar-2026, DOI: 10.4172/2155-9864.26.S19.001

Description

Blood transfusion remains an essential component of modern healthcare, supporting patients undergoing surgery, trauma care, cancer treatment, organ transplantation, and management of hematological disorders. While transfusion medicine has advanced considerably over the past decades, the process still involves risks that require continuous observation and evaluation. Hemovigilance surveillance systems have emerged as organized frameworks designed to monitor, document, assess, and reduce adverse events associated with blood donation and transfusion activities. These systems contribute to safer clinical practices by collecting information from every stage of the transfusion chain, beginning with donor recruitment and extending through blood collection, processing, storage, distribution, and patient administration.

A well-designed hemovigilance system functions as a continuous cycle of observation and improvement. Healthcare professionals report incidents ranging from mild allergic reactions to more serious events such as transfusion-associated circulatory overload, acute hemolytic reactions, bacterial contamination, and transfusion-related acute lung injury. Information gathered from these reports is examined by specialists who determine possible causes and recommend actions aimed at preventing recurrence. Through this approach, healthcare institutions gain valuable insight into operational weaknesses and opportunities for quality enhancement.

The effectiveness of any surveillance system depends heavily on the quality of reporting. Underreporting remains a challenge in many healthcare settings. Some adverse reactions may go unrecognized, while others may not be documented because of workload pressures or uncertainty regarding reporting requirements. Educational initiatives play an important role in addressing these obstacles. Clinicians, nurses, laboratory specialists, and blood bank personnel must understand both the importance of reporting and the procedures involved. Creating a culture that values transparency and learning encourages greater participation and improves the completeness of surveillance data.

Donor safety represents another significant aspect of hemovigilance. Surveillance activities are not limited to recipients of blood products. Blood donors may experience adverse events such as vasovagal reactions, bruising, nerve irritation, or complications associated with apheresis procedures. Monitoring these events helps blood collection organizations refine donor selection processes, improve collection techniques, and enhance donor care. Maintaining donor confidence is essential because a reliable donor population supports the stability of national blood supplies.

International collaboration has contributed substantially to the development of hemovigilance practices. Many countries share surveillance data, standardized definitions, and reporting methodologies, allowing broader understanding of transfusion-related complications. Collaborative networks promote consistency in data interpretation while supporting multicenter research that improves transfusion safety worldwide. Shared experiences also enable healthcare systems to adopt successful preventive strategies developed elsewhere.

Patient participation also contributes to comprehensive surveillance. Educating recipients about potential symptoms following transfusion encourages timely reporting of delayed reactions that may occur after hospital discharge. Providing clear instructions regarding warning signs and follow-up appointments supports early diagnosis while improving overall clinical management.

Conclusion

The continued development of comprehensive surveillance frameworks will remain important as transfusion medicine advances. New blood products, emerging pathogens, evolving therapeutic approaches, and changing healthcare environments introduce fresh challenges that require careful monitoring. Through sustained investment in reporting infrastructure, professional education, technological innovation, and collaborative networks, hemovigilance systems can continue supporting high standards of transfusion safety and quality. Their contribution lies not only in identifying complications but also in transforming collected information into meaningful improvements that benefit donors, patients, healthcare professionals, and society as a whole.

References

1. Haddad A, Abu-Helu R, Khadijetou BA, Assi TB, Benajiba M, Slama H, et al. How to improve issuing, transfusion and follow-up of blood components in Southern and Eastern Mediterranean countries? A benchmark assessment. Transfus Apher Sci. 2023;62(2):103616.

   [Crossref][Google scholar][Pubmed]

2. Vuk T. The future of quality management in transfusion medicine–From the new SoHo regulation and beyond. Transfus Clin Biol. 2025.

   [Crossref] [Google scholar] [Pubmed]

3. He M, Wang J, Chen L, Liu J, Zeng P. The impact of emerging infectious diseases on Chinese blood safety. Transfus Med Rev. 2017;31(2):94-101.

   [Crossref][Google scholar][Pubmed]

4. Tóth GE, Petersen M, Chevenet F, Sikora M, Tomazatos A, Bialonski A, et al. Blood donors as sentinels for genomic surveillance of West Nile virus in Germany using a sensitive amplicon-based sequencing approach. J Infect. 2025:106647.

   [Crossref] [Google scholar] [Pubmed]

5. Joseph L, Driessen M. A comprehensive view of pregnancy in patients with sickle cell disease in high-income countries: the need for robust data and further decline in morbidity and mortality. Lancet Haematol. 2024;11(1):e75-84.

   [Crossref][Google scholar][Pubmed]

6. Piel FB, Rees DC, DeBaun MR, Nnodu O, Ranque B, Thompson AA, et al. Defining global strategies to improve outcomes in sickle cell disease: a Lancet Haematology Commission. Lancet Haematol. 2023;10(8):e633-686.

   [Crossref][Google scholar][Pubmed]

7. Atun R, Bhakta N, Denburg A, Frazier AL, Friedrich P, Gupta S, et al. Sustainable care for children with cancer: a Lancet Oncology Commission. Lancet Oncol. 2020;21(4):e185-224.

   [Crossref][Google scholar][Pubmed]

8. Wood EM, Whitaker BI, Townsend M, Narayan S. How we forecast tomorrow’s haemovigilance. Transfus Clin Biol. 2024;31(2):114-118.

   [Crossref][Google scholar][Pubmed]

9. Johns C, Bakhtary S, Wu R, Nedelcu E. A single-centre description of pediatric transfusion reactions and preventable patient harm. Hosp Pediatr. 2021;11(11):e334-338.

   [Crossref][Google scholar][Pubmed]

10. Yanagisawa R, Shimodaira S, Sakashita K, Hidaka Y, Kojima S, Nishijima F, et al. Factors related to allergic transfusion reactions and febrile non�haemolytic transfusion reactions in children. Vox Sanguinis. 2016;110(4):376-384.

    [Crossref][Google scholar][Pubmed]